To investigate whether complement activation is required to produce AQP4 loss following intravitreal AQP4-IgG injection, studies were done in rats treated with CVF, which inactivates complement and was shown previously to prevent NMO pathology following intracerebral injection of AQP4-IgG in rats [19]. Here, AQP4 is linked to neuromyelitis optica.